Pharmaxis press release link here. The Australian government has approved a new, simplified Pharmaceutical Benefits Scheme (PBS) status for Bronchitol in the treatment of cystic fibrosis (CF). Following the successful Pharmaxis application to the Pharmaceutical Benefits Advisory Committee (PBAC) and discussions with the Department of Health and Ageing, the new Bronchitol PBS listing removes the restrictive […]
Avita Medical press release link here.
Biota Pharmaceuticals press release link here. ATLANTA, Aug. 19, 2013 (GLOBE NEWSWIRE) — Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (“Biota” or the “Company”), a biopharmaceutical company focused on the discovery and development of anti-infective products to prevent and treat serious and potentially life-threatening infectious diseases, today announced changes to its Board of Directors, including the resignation of Dr. Jeffrey […]
AmpliPhi press release link here. Data presented at the 20th Biennial Evergreen International Phage Meeting, 4-9 August 2013, Evergreen State College, Olympia, WA, USA RICHMOND, Va. & SYDNEY & LONDON–(BUSINESS WIRE)–Aug. 8, 2013– AmpliPhi BioSciences Corp. (OTC: APHB) (“AmpliPhi”), the leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant bacterial infections, yesterday presented data relating to the use of bacteriophages in the […]
AmpliPhi press release link here. AmpliPhi Signs Global R&D Agreement with US Army to Develop Bacteriophage Therapies to Treat Resistant Bacterial Infections RICHMOND, VA, US, SYDNEY, AUSTRALIA, London UK, July 1, 2013 – AmpliPhi BioSciences Corporation (OTC: APHB) (“AmpliPhi”), the leader in the discovery and development of bacteriophage-based therapies to treat drug resistant bacterial infections, announced […]
BioScience Managers Pty Ltd (formerly Octa Phillip Bioscience Managers) today fully endorsed the move by Bioxyne Ltd (ASX:BXN) to acquire Asia Pacific medical device company, Vitality Devices Pty Ltd. Following Bioxyne’s existing product HI-164OV failing to reach clinical trial endpoints last year, BioScience Managers, a 20+% shareholder in BXN, has been at the forefront of […]
IB Australian Bioscience Fund I, managed by Octa Phillip Bioscience Managers (OPBM, formerly IB Managers) has today entered into a conditional Subscription Agreement to invest NZD$2.5 million into Claridge Capital (NZX.CLA) in conjunction with Claridge’s acquisition of SeaDragon Marine Oils. The subscription arrangement is conditional upon the satisfaction of a number of commercial conditions. The […]